MetaCap

Quest Diagnostics Incorporated (DGX)

NYSE: DGXHealth CareMedical SpecialitiesUSD

258.28-0.81 (-0.31%)

At close: Nov 20, 4:01 PM ET · Delayed 15 min

DGX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$28.42B
EPS (TTM)
$10.04
Dividend yield
1.31% ($3.38)
Ex-dividend date
Oct 6, 2026
52-week range
171.18 – 263.19
Day range
257.56 – 262.96
Volume / Avg
1.37M / 1.03M
Beta
—

52-week range

$171.18$263.19

DGX stock today

Quest Diagnostics (DGX) closed at $258.28 on Nov 20, down 0.31% (-$0.81), versus the S&P 500's 3.70% decline. Shares are 1.9% below their 52-week high of $263.19, set on Nov 16, 2026 and 50.9% above the 52-week low of $171.18, near the top of the past year's range. DGX is up 48.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.0%.

At 25.7x trailing earnings, Quest Diagnostics trades below the peer-group median of 30.1x. Its forward P/E of 21.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Quest Diagnostics pays an annual dividend of $3.38 per share, a 1.31% yield at the current price.

Summary generated from market data by MetaCap's automated system. Methodology

About Quest Diagnostics

Company profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.

Industry
Medical Specialities
CEO
Mr. James E. Davis
Headquarters
Secaucus, NJ
Employees
60,000

Financial highlights

Full financials

In fiscal 2025, Quest Diagnostics generated $11.04 billion in revenue, up 11.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $992.0 million (+13.9% year over year), for a net margin of 9.0% versus a median of 9.6% in the prior 5 years. Gross margin was 33.2% (up from 32.9%) and operating margin 14.1%.

Quest Diagnostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$11.04B$9.87B$9.25B$9.88B$10.79B
Growth+11.78%+6.70%-6.38%-8.39%+14.32%
Net income$992.00M$871.00M$854.00M$946.00M$2.00B
EPS (diluted)$8.75$7.69$7.49$7.97$15.55

Analyst forecast

Forecast

Consensus (17 analysts)

buy

Avg. price target

$257.27-0.39%

  • Strong buy 2
  • Buy 7
  • Hold 8
  • Sell 0
  • Strong sell 0

Target range

Low $235.00High $279.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 22, 2026
EPS actual vs est.
$3.00 vs $2.85
Surprise
+5.26%

Dividends

Dividend history
Annual dividend
$3.38
Last payment
$0.86
Ex-dividend date
Oct 6, 2026

DGX news

All DGX news

Quest Diagnostics peers

Health Care sector
DGX peer companies
CompanyPrice% ChgMarket capCompare
ILMNIllumina Inc.192.82-3.90%$29.15Bvs DGX
LHLabcorp Holdings Inc.367.13-0.47%$29.81Bvs DGX
CNCCentene Corporation63.78-2.74%$31.58Bvs DGX
GHGuardant Health Inc.145.83+0.16%$19.73Bvs DGX
NTRANatera Inc.273.40-5.70%$39.64Bvs DGX
MOHMolina Healthcare Inc198.39-2.43%$10.36Bvs DGX
HUMHumana Inc.390.00+2.63%$46.84Bvs DGX
HSICHenry Schein Inc.83.52-1.51%$9.23Bvs DGX

Indexes, lists and sector

Quest Diagnostics stock FAQ

What is Quest Diagnostics's stock price today?

DGX last traded at $258.28 as of Nov 20, 4:01 PM EST, down 0.31% on the day. Prices are delayed at least 15 minutes.

Does Quest Diagnostics pay a dividend?

Yes. Quest Diagnostics pays $3.38 per share annually, a 1.31% yield. The most recent dividend of $0.86 had an ex-dividend date of Oct 6, 2026.

What is DGX's P/E ratio?

DGX trades at a trailing P/E ratio of 25.73 and a forward P/E of 21.55, compared with a median of 30.1 for its closest peers.

Is Quest Diagnostics in the S&P 500?

Yes. Quest Diagnostics (DGX) is a constituent of the S&P 500 index.

Who is Quest Diagnostics's CEO?

Mr. James E. Davis is the chief executive officer of Quest Diagnostics Incorporated, which has about 60,000 employees.

Has DGX ever split its stock?

Yes. The most recent DGX stock split was a 2-for-1 split on Jun 21, 2005, one of 2 splits on record.

What is the DGX 52-week high?

The 52-week high for DGX is $263.19 and the 52-week low is $171.18. The stock is currently 1.9% below its high.

Compare DGX